ResearchMoz

Dialysis Partnering 2007-2013

Current Partnering
Published Date » 2013-07-01
No. Of Pages » 100

The Dialysis Partnering 2007-2013 provides understanding and access to the dialysis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of dialysis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dialysis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 30 links to online copies of actual dialysis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of dialysis partnering trends.

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in dialysis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading dialysis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of dialysis partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dialysis technologies and products.

Report scope

Dialysis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to dialysis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in dialysis dealmaking in the biopharma industry since 2007 
  • Access to summary headline, upfront, milestone and royalty data 
  • The leading dialysis deals by value since 2007 

In Dialysis Partnering 2007-2013, the available deals are listed by:

  • Headline value 
  • Upfront payment value 
  • Royalty rate value 
  • Company A-Z 
  • Industry sector 
  • Stage of development at signing 
  • Deal component type 
  • Technology type 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in dialysis partnering
2.1. Introduction
2.2. Dialysis partnering over the years
2.3. Bigpharma dialysis dealmaking activity
2.4. Dialysis partnering by deal type
2.5. Dialysis partnering industry sector
2.6. Dialysis partnering by stage of development
2.7. Dialysis partnering by technology type
2.8. Disclosed financial deal terms for dialysis partnering
2.8.1 Dialysis headline values
2.8.2 Dialysis upfront payments
2.8.3 Dialysis milestone payments
2.8.4 Dialysis royalty rates

Chapter 3 Leading dialysis deals
3.1. Introduction
3.2. Top dialysis deals by value
3.3. Top dialysis deals involving bigpharma

Chapter 4 Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports

List of Tables

NA

List of Figures


Figure 1: Dialysis partnering since 2007 
Figure 2: Bigpharma top 50 dialysis deals 2007 to 2011 
Figure 3: Bigpharma dialysis deal frequency 2007 to 2011 
Figure 4: Dialysis partnering by deal type since 2007 
Figure 5: Dialysis partnering by industry sector since 2007 
Figure 6: Dialysis partnering by stage of development since 2007 
Figure 7: Dialysis partnering by technology type since 2007 
Figure 8: Dialysis deals with a headline value 
Figure 9: Dialysis deals with upfront payment values 
Figure 10: Dialysis deals with milestone payments 
Figure 11: Dialysis deals with royalty rates, % 
Figure 12: Top dialysis deals by value since 2007 
Figure 13: Top dialysis deals signed by bigpharma value since 2007 
Figure 14: Online partnering resources 
Figure 15: Forthcoming partnering events 
Figure 16: Deal type definitions

Upcoming Reports:

Wood Preservation Chemicals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Wood is an essential building material and has several indoor and outdoor applications. Any attack by insects, fungus or bacteria can spoil the condition of the wood. Thus, wood preservation chemicals are used to ensure long lasting life and sustainability of woods in the face of the changing environment and bacterial or fungal attacks. There are several treatments and chemicals used for such preservation. The wood preservation chemical market has a bright future as it is growing at a high rate. The coming six years would see a boom in this market since wood is finding increasing...
Emulsifiers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Emulsification is a process of mixing two or more immiscible liquids with the help of an emulsifier, which is also known as an emulsifying agent. Emulsifiers help to stabilize the mixture by reducing the surface tension of the emulsion. They have major applications in food, in making of many products like ice-creams, biscuits, cake, bread, caramel, and others. In addition to this, emulsifiers are also used in detergents, medicines, and fire extinguishers. Emulsifiers are commonly used in hair styling products and cosmetics. These agents can be majorly classified into natural,...
Inhalation & Nasal Spray Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Generic drugs are drugs that are not associated with any company or a brand name and are subject to regulation of countries where they are dispensed. According to US FDA generic medicines are drugs that are identical or within an acceptable bioequivalent range with respect to pharmacokinetics and pharmacodynamics properties of branded drugs. More than 75% of the respiratory prescription drugs are delivered using inhalation or nasal spray technology. High revenue generator drugs are undoubtedly attracting the interest of generic drug manufacturers due to low cost of manufacturing. Though...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...